Liver-directed therapy in metastatic colorectal cancer. Issue 8 (3rd August 2017)

• Record Type: Journal Article
• Authors: Kelly, Ciara M.; Kemeny, Nancy E.
• Is Part Of: Expert review of anticancer therapy. Volume 17:Issue 8(2017)
• Page Start: 745
• Page End: 758
• Publication Date: 2017-08-03
• Subjects: Colorectal cancer -- liver metastases -- oligometastatic -- hepatic arterial infusion therapy -- radiofrequency ablation -- selective internal radiation therapy -- transarterial chemoembolization; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2017.1345629
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction : Colorectal cancer is a significant global health issue with over 1 million cases diagnosed annually throughout the world. 15% of patients diagnosed with colorectal cancer will have liver metastases and 60% will develop liver metastases if they have metastatic disease. Oligometastatic colorectal cancer confined to the liver represents an intermediate state in the evolution of metastatic capacity that opens the opportunity for local interventions. Areas covered : The literature supports long-term survival if patients undergo liver resection of colorectal metastases. This article reviews the liver-directed therapeutic strategies available for the management of metastatic liver disease including hepatic arterial infusion therapy, radiofrequency ablation, radiation therapy and transarterial chemoembolization. Expert commentary : Great advances have been made with the use of liver directed therapies. In the USA using hepatic arterial infusions with FUDR and Decadron along with systemic therapy, 5 year survivals after liver resection have improved. In Europe with the use of HAI of Oxaliplatin, more patients have been able to get to resection and have obtained higher survival rates, even in second line therapy. New advances in ablative therapy have improved results to get all disease treated at resection for the treatment of reccurrence